# OnCo record calla (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/calla/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "calla", "NCT03830866" ;
  schema:name "CALLA"@en ;
  schema:description "CALLA tested adding the PD-L1 antibody durvalumab to chemoradiotherapy for locally advanced cervical cancer and found no significant benefit, in contrast to the later positive KEYNOTE-A18 trial of pembrolizumab in a higher-risk population."@en ;
  schema:url <https://onco.cc/trials/calla/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03830866> ;
  onco:status "negative" ;
  onco:tag "subtype-trials" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/locally-advanced-cervical-cancer/>, <https://onco.cc/cancers/cervical/> ;
  onco:drugs <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/cisplatin/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> ;
  onco:people <https://onco.cc/people/bradley-monk/> .